Scientists have uncovered evidence linking a once-rare form of deadly digestive blood clots to Covid mRNA “vaccines.”
During a study led by Dr. Guneet Sidhu, a professor of medicine at the University of North Dakota, the researchers found that Covid injections cause splanchnic vein thrombosis (SVT).
SVT is a life-threatening condition that occurs when blood clots form in the veins of the splanchnic circulation.
The splanchnic circulation drains the digestive system from the lower esophagus to the upper two-thirds of the rectum.
The results of the study, which was conducted with researchers from the Vascular Liver Disease Group (VALDIG), were published in the November 2024 issue of the renowned medical journal Hepatology.
Dr. Sidhu teamed up with the VALDIG researchers to conduct a comprehensive study investigating a surge in cases of SVT occurring post-Covid vaccination.
The research team noted in a separate study that Covid “vaccine” caused an “extensive” spike in SVT.
“Since the introduction of SARS-CoV-2 vaccines, several cases of vaccine-induced immune thrombocytopenia and thrombosis (VITT) have been described, especially cerebral vein thrombosis,” The researchers note.
They explain that new cases skyrocketed after the injections were rolled out for public use, specifically between April 2021 and April 2022.
In the “Conclusions” section of the study’s paper, the researchers confirmed that no other cause of the spike in VITT or SVT could be identified aside from Covid “vaccines.”
In addition, they note that the spike only occurred in patients who had been vaccinated for Covid.
The findings of this study are more troubling, however.
The study found that not only are Covid mRNA injections causing a spike in splanchnic vein thrombosis, but the post-Covid “vaccine” SVT is far more severe than cases affecting unvaccinated people.
The researchers noted that the severity of post-Covid “vaccine” SVT was highly disturbing.
Dr. Sidhu, the principal investigator, made a significant call to action to providers to monitor for SVT related to Covid shots, predominantly associated with AstraZeneca, a viral vector vaccine withdrawn from the market, and Pfizer-BioNTech, the mRNA vaccine still on the market.
Involving 29 patients across 13 trial site centers in 6 nations, investigators sought to better understand clinical outcomes and severity of SVT post-Covid vaccination.
The findings raise significant concern, to the point that the authors emphasize the outcomes point to an imminent need for awareness and management of the deadly condition.
The majority of the incidents were associated with the AstraZeneca shot and Pfizer’s mRNA “vaccine.”
The median average onset time for vaccine-induced thrombosis was 11 days, but this ranged from 2 to 76 days.
Occurrence/Dose
| Dose | % |
| 1st dose | 48% |
| 2nd dose | 41% |
| 3rd dose | 10% |
This vaccine-induced SVT is incredibly aggressive, according to the authors.
69% of patients presenting with SVT at multiple sites, plus another “14% presenting concomitant extra-abdominal thrombosis.”
Diagnostically, they are difficult.
The comparison was made between a Covid vaccine-triggered SVT and an unvaccinated SVT cohort.
The post-vaccination group experienced overall more severe SVT, including bowel ischemia, a rare condition that occurs when blood flow to the intestines is reduced or stopped.
To put it all in perspective, among the post-vaccine SVT cohort, 63% necessitated excessive bowel resections due to severe mesenteric ischemia.
Contrast this with the unvaccinated SVT cohort, where only 3% of those involved needed such interventions.
Mortality rates also revealed another alarming and extreme outcome.
In the post-Covid vaccine-induced SVT 7% of the total population died, compared to 2% in the unvaccinated control group.
The researchers also made another extreme observation.
Of the vaccine injury group, 3% required liver transplantation.
This was compared to just 0.02% in the unvaccinated SVT group.
The authors raised the alarm over the extreme findings, warning:
“These findings highlight the significant risk of severe outcomes, including death and the need for major surgical interventions, in patients with SVT following SARS-CoV-2 vaccination.”
Due to their explosive findings, the authors issued a call to action for physicians, emphasizing the “importance of heightened clinical vigilance and the need for standardized diagnostic approaches to manage SVT in the context of COVID-19 vaccination.”
